Magnetic resonance imaging-quantified small bowel motility is a sensitive marker of response to medical therapy in Crohn's disease

Alimentary Pharmacology and Therapeutics

Volumn 42, Issue 3, 2015, Pages 343-355

  Plumb, A A ^a   Menys, A ^a   Russo, E ^b   Prezzi, D ^a,c   Bhatnagar, G ^a   Vega, R ^d   Halligan, S ^a   Orchard, T R ^b   Taylor, S A ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; INFLIXIMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; BIOLOGICAL MARKER; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGE DISTRIBUTION; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DIAGNOSTIC ACCURACY; FEMALE; HARVEY BRADSHAW INDEX; HUMAN; INTESTINE MOTILITY; INTESTINE RADIOGRAPHY; MAGNETIC RESONANCE ENTEROGRAPHY; MAGNETIC RESONANCE INDEX OF ACTIVITY SCORE; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICIAN GLOBAL ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SCORING SYSTEM; SEX DIFFERENCE; SMALL BOWEL MOTILITY; TREATMENT RESPONSE; ADOLESCENT; AGED; ALGORITHM; ANTAGONISTS AND INHIBITORS; METABOLISM; MIDDLE AGED; PROCEDURES; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALGORITHMS; BIOMARKERS; C-REACTIVE PROTEIN; CROHN DISEASE; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 84936847532     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.13275     Document Type: Article

References (31)

1. Dretzke J, Edlin R, Round J, et al,. A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn's disease. Health Technol Assess 2011; 15: 1-244.
2. Best WR, Becktel JM, Singleton JW, et al,. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70: 439-44.
3. Ben-Horin S, Chowers Y,. Review article: loss of response to anti-TNF treatments in Crohn's disease. Aliment Pharmacol Ther 2011; 33: 987-95.
4. D'Haens G, Feagan B, Colombel JF, et al,. Challenges to the design, execution, and analysis of randomized controlled trials for inflammatory bowel disease. Gastroenterology 2012; 143: 1461-9.
5. Panes J, Bouhnik Y, Reinisch W, et al,. Imaging techniques for assessment of inflammatory bowel disease: joint ECCO and ESGAR evidence-based consensus guidelines. J Crohns Colitis 2013; 7: 556-85.
6. Van Assche G, Herrmann KA, Louis E, et al,. Effects of infliximab therapy on transmural lesions as assessed by magnetic resonance enteroclysis in patients with ileal Crohn's disease. J Crohns Colitis 2013; 7: 950-7.
7. Cullmann JL, Bickelhaupt S, Froehlich JM, et al,. MR imaging in Crohn's disease: correlation of MR motility measurement with histopathology in the terminal ileum. Neurogastroenterol Motil 2013; 25: 749-e577.
8. Menys A, Atkinson D, Odille F, et al,. Quantified terminal ileal motility during MR enterography as a potential biomarker of Crohn's disease activity: a preliminary study. Eur Radiol 2012; 22: 2494-501.
9. Biological therapies audit sub group. National clinical audit report of biological therapies. Adult national report. UK IBD audit. London: Royal College of Physicians, 2013.
10. Satsangi J, Silverberg MS, Vermeire S, et al,. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006; 55: 749-53.
11. Odille F, Menys A, Ahmed A, et al,. Quantitative assessment of small bowel motility by nonrigid registration of dynamic MR images. Magn Reson Med 2012; 68: 783-93.
12. Menys A, Plumb A, Atkinson D, et al,. The challenge of segmental small bowel motility quantitation using MR enterography. Br J Radiol 2014; 87: 20140330.
13. Rimola J, Rodriguez S, García-Bosch O, et al,. Magnetic resonance for assessment of disease activity and severity in ileocolonic Crohn's disease. Gut 2009; 58: 1113-20.
14. Ordas I, Rimola J, Rodriguez S, et al,. Accuracy of magnetic resonance enterography in assessing response to therapy and mucosal healing in patients with Crohn's disease. Gastroenterology 2014; 146: 374-82 e1.
15. Tielbeek JA, Lowenberg M, Bipat S, et al,. Serial magnetic resonance imaging for monitoring medical therapy effects in Crohn's disease. Inflamm Bowel Dis 2013; 19: 1943-50.
16. Reinisch W, Wang Y, Oddens BJ, et al,. C-reactive protein, an indicator for maintained response or remission to infliximab in patients with Crohn's disease: a post-hoc analysis from ACCENT I. Aliment Pharmacol Ther 2012; 35: 568-76.
17. Bland JM, Altman DG,. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-10.
18. Rao SS, Read NW, Brown C, et al,. Studies on the mechanism of bowel disturbance in ulcerative colitis. Gastroenterology 1987; 93: 934-40.
19. Reddy SN, Bazzocchi G, Chan S, et al,. Colonic motility and transit in health and ulcerative colitis. Gastroenterology 1991; 101: 1289-97.
20. Tursi A, Brandimarte G, Giorgetti G, et al,. Assessment of orocaecal transit time in different localization of Crohn's disease and its possible influence on clinical response to therapy. Eur J Gastroenterol Hepatol 2003; 15: 69-74.
21. Gutzeit A, Patak MA, Von Weymarn C, et al,. Feasibility of small bowel flow rate measurement with MRI. J Magn Reson Imaging 2010; 32: 345-51.
22. Nadorra R, Landing BH, Wells TR,. Intestinal plexuses in Crohn's disease and ulcerative colitis in children: pathologic and microdissection studies. Pediatr Pathol 1986; 6: 267-87.
23. Annese V, Bassotti G, Napolitano G, et al,. Gastrointestinal motility disorders in patients with inactive Crohn's disease. Scand J Gastroenterol 1997; 32: 1107-17.
24. Nobrega AC, Ferreira BR, Oliveira GJ, et al,. Dyspeptic symptoms and delayed gastric emptying of solids in patients with inactive Crohn's disease. BMC Gastroenterol 2012; 12: 175.
25. Targan SR, Hanauer SB, van Deventer SJ, et al,. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997; 337: 1029-35.
26. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
27. Hebuterne X, Lemann M, Bouhnik Y, et al,. Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut 2013; 62: 201-8.
28. Rutgeerts P, Van Assche G, Sandborn WJ, et al,. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012; 142: 1102-11. e2
29. Vermeire S, Schreiber S, Sandborn WJ, et al,. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity. Clin Gastroenterol Hepatol 2010; 8: 357-63
30. Rimola J, Planell N, Rodriguez S, et al,. Characterization of inflammation and fibrosis in Crohn's disease lesions by magnetic resonance imaging. Am J Gastroenterol 2015; 110: 432-40.
31. Menys A, Taylor SA, Emmanuel A, et al,. Global small bowel motility: assessment with dynamic MR imaging. Radiology 2013; 269: 443-50.